1. Nakano K, Pinnow E, Flaws JA, et al. Reproductive history and hot flashes in perimenopausal women. J Womens Health. 2012;Jan 27 [Epub ahead of print].
2. Li S, Holm K. Physical activity alone and in combination with hormone replacement therapy on vasomotor symptoms in postmenopausal women. West J Nurs Res. 2003;25:274-288.
3. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96:1226-1235.
4. Hall E, Frey B, Soares C. Non-hormonal treatment strategies for vasomotor symptoms. Drugs. 2011;7:287-304.
5. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Womens Health. 2009;5:361-384.
6. Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.-
7. Hoffmann M, Hammar M, Kjeligren KI, et al. Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas. 2005;52:11-17.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
9. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
10. Schenck-Gustafsson K, Brincat M, Erel CT, et al. EMAS position statement: managing the menopause in the context of coronary heart disease. Maturitas. 2011;68:94-97.
11. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med. 2005;118(suppl 12B):74-78.
12. Taylor H, Manson J. Update in hormone therapy use in menopause. J Clin Endocrinol Metab. 2011;96:255-264.
13. Grady D, Ettinger B, Tosteson AN, et al. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol. 2003;102:1233-1239.
14. Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet. 1998;351:1255-1256.
15. Wren BG, Champion SM, Willets K, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods and quality of life for postmenopausal women. Menopause. 2003;10:13-18.
16. Sites C. Bioidentical hormones for the menopausal therapy. Womens Health. 2008;4:163-171.
17. Grady D, Cohen B, Tice J, et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol. 2007;109:823-830.
18. Gordon PR, Kerwin JP, Boesen KG, et al. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general populations. Menopause. 2006;13:568-575.
19. Woods NF, Smith-DeJulio K, Percival DB, et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause. 2008;15:223-232.
20. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2007;103:267-272.
21. Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007;24:448-461.
22. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized controlled trial. Obstet Gynecol. 2005;105:161-166.
23. Joffee H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68:943-950.
24. Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned placebo controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200:172e1-e10.
25. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry. 2003;64:473-479.
26. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17:700-711.
27. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578-1583.
28. Stearns V, Slack E, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23:6919-6930.
29. Soares CN, Joffee H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med. 2008;121:159-162.
30. Gordon PR, Kerwin JP, Boessen KG, et al. Sertraline to treat hot flashes: a randomized controlled double blind crossover trial in a general population. Menopause. 2006;13:568-575.
31. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101:337-345.
32. Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15:310-318.
33. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006;108:41-48.
34. Thurston RC, Joffee H, Soares CN, et al. Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. Menopause. 2006;13:553-560.
35. Borud EK, Alraek T, White A, et al. The Acupuncture on hot flushes among menopausal women (ACUFLASH) study, a randomized control trial. Menopause. 2009;16:484-493.
36. Borud EK, Alraek T, White A, et al. The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause. 2010;17:262-268.
37. Geller SE, Shulman LP, van Breeman RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause. 2009;16:1156-1166.
38. Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's Wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause. 2010;17:326-331.
39. Freeman MP, Hibbeln JR, Silver M, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause. 2011;18:279-284.
40. Park H, Parker GL, Boardman JR, et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer. 2011;19:859-862.
41. Joffee H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized double blinded placebo controlled crossover trial. Am J Obstet Gynecol. 2010;202:171.e1-171.e11.
42. Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes , associated or not with a natural anxiolytic agent in menopause. Minerva Ginecol. 2011;63:11-17.
43. Sturdee D, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13:509-522.
44. Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA. 1983;249:2195-2198.
45. Al-Baghdadi O, Ewies A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date review. Climacteric. 2009;12:91-105.
46. Weed SS. Menopausal Years: The Wise Woman Way. Alternative Approaches for Women. Woodstock, NY: Ash Tree; 1992.
47. Yildrim B, Kaleli B, Duzcan E, et al. The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas. 2004;49:334-347.
48. Catelo-Branco CC, Cancelo MJ, Villero J, et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52(suppl 1):S46-S52.
49. LeVeque F, Hendrix S. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy induced amenorrhea in premenopausal women. J Clin Oncol. 2004;22(suppl):8099.-
50. Ali I, Wojnarowska F. Physiological changes in scalp, facial and body hair after the menopause: a cross-sectional population-based study of subjective changes. Br J Dermatol. 2011;164:508-513.
51. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28:611-618.
52. Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol. 2003;48:253-262.
53. Dawber RP, Sonnex T, Ralfs I. Oral antiandrogen treatment of common baldness in women. Br J Dermatol. 1982;107 (suppl):20-21.